Plain-English translation of NCT07601074 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a medication called DARE-HPV to see if it can help clear persistent high-risk HPV (human papillomavirus) infections of the genital area. Researchers want to find the best dose and treatment length — either 14 or 21 days — by comparing the medication to a placebo (a dummy treatment with no active ingredient). They'll check whether the infection clears within 30, 60, or 90 days after treatment ends.
Many women have persistent high-risk HPV infections that their bodies don't clear on their own, and there are limited treatment options available. This trial is exploring whether this new medication could help women's bodies finally eliminate the virus.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to receive either the new medication or a placebo for either 14 or 21 days. You'll need to avoid intercourse, tampons, douching, and other vaginal products for 48 hours before you start treatment and 72 hours after you finish. The study team will check whether the HPV infection has cleared at 30, 60, and 90 days after your treatment ends through follow-up visits and testing.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
United States